Table 3.
The percentage of each cell cycle phase under various treatments in ABCB1/Flp-InTM-293 cell line and KB/VIN cell line.
| ABCB1/Flp-InTM-293 | Percentage of Phase ± SE (%) | |||
| Sub G1 | G0/G1 | S | G2/M | |
| Control | 0.4 ± 0.17 | 35.7 ± 1.5 | 46.2 ± 2.9 | 17.6 ± 4.3 |
| Paclitaxel 250 nM | 11.3 ± 0.2 | 27.4 ± 0.6 | 29.3 ± 1.6 | 31.8 ± 1.3 |
| Caffeic acid 20 μg/mL | 3.7 ± 0.6 | 27.4 ± 0.6 | 29.3 ± 1.6 | 31.8 ± 1.3 |
| Caffeic acid 25 μg/mL | 1.2 ± 0.1 | 41.7 ± 0.5 | 37.7 ± 0.2 | 19.2 ± 0.6 |
| Paclitaxel 250 nM + Caffeic acid 20 μg/mL | 24.1 ± 0.3 | 36.6 ± 1.4 | 24.1 ± 1.8 | 15.0 ± 0.5 |
| Paclitaxel 250 nM + Caffeic acid 25 μg/mL | 33.0 ± 9.0 | 27.5 ± 8.5 | 29.7 ± 4.8 | 14.8 ± 0.6 |
| KB/VIN | Percentage of Phase ± SE (%) | |||
| Sub G1 | G0/G1 | S | G2/M | |
| Control | 0.6 ± 0.07 | 37.3 ± 4.0 | 39.2 ± 0.7 | 22.9 ± 3.3 |
| Paclitaxel 250 nM | 12.8 ± 1.5 | 44.6 ± 1.0 | 29.2 ± 0.4 | 13.3 ± 0.1 |
| Caffeic acid 20 μg/mL | 1.5 ± 0.04 | 40.3 ± 0.9 | 45.5 ± 1.3 | 12.8 ± 0.5 |
| Caffeic acid 25 μg/mL | 1.3 ± 0.1 | 37.2 ± 0.4 | 50.1 ± 0.5 | 11.4 ± 0.3 |
| Paclitaxel 250 nM + Caffeic acid 20 μg/mL | 13.2 ± 1.2 | 44.3 ± 0.5 | 31.6 ± 1.0 | 11.0 ± 0.2 |
| Paclitaxel 250 nM + Caffeic acid 25 μg/mL | 12.7 ± 1.3 | 46.9 ± 0.1 | 23.6 ± 1.5 | 16.8 ± 0.2 |